SCHEMBL6426003

SCHEMBL6426003

O=C(O)C(c1ccccc1)c1ncco1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.44
CTSA P10619 8/20 0.41
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
GAA P10253 1/20 0.40
SRC P12931 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
LMNA P02545 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4805668 0.87 CTSA (0.42) CTSATDP1L3MBTL1ALDH1A1CYP1A2
SCHEMBL10504782 0.81 KMT2A (0.49) CTSATDP1L3MBTL1ALDH1A1LMNA
SCHEMBL27622261 0.80 CYP2D6 (0.46) CYP2D6CTSASRCLMNAMAPK1
SCHEMBL13733183 0.80 KDM4C (0.38) CTSA
SCHEMBL474256 0.77 SMN1; SMN2 (0.48) CTSAALDH1A1GAALMNAKDM4E
SCHEMBL11078590 0.76 MAPT (0.39) CTSAL3MBTL1ALDH1A1CYP1A2KDM4E
SCHEMBL8551224 0.75 CA2 (0.46) CTSA
SCHEMBL9030789 0.74 CTSA (0.46) CTSA
SCHEMBL8146051 0.73 CTSA (0.39) CTSATDP1SRCKDM4E
SCHEMBL4327553 0.73 CTSA (0.41) CTSAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113433-A1 Compositions of a phenyl acetic acid cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system PHARMACIA CORPORATION 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113433-A1 Compositions of a phenyl acetic acid cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system ACHE, CHRNA2, CHRM2 CYP2D6 2048/4885CTSA 613/4885TDP1 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.